Form 4: Revolution Medicines Director Sandra Horning Boosts Equity Holdings with Share and Option Grants

Revolution Medicines, Inc. Director Sandra Horning acquired 3,142 shares of common stock and 11,574 stock options on June 26, 2025, increasing her beneficial ownership in the company.

Summary

• Director Sandra Horning acquired 3,142 shares of Revolution Medicines, Inc. common stock on June 26, 2025, at a price of $0.
• Following this transaction, Sandra Horning beneficially owns 96,574 shares of common stock, which includes 8,392 Restricted Stock Units.
• Sandra Horning also acquired 11,574 stock options to buy common stock on June 26, 2025, with an exercise price of $37.48 and an expiration date of June 26, 2035.
• These stock options will vest in full on the earlier of the first anniversary of June 26, 2025, or immediately prior to the Annual Meeting following the grant date, contingent on her continued service as a Service Provider.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a director is generally a positive signal, indicating continued commitment and alignment with shareholder interests. It's a routine compensation event, not necessarily a strong buy signal, but certainly not negative.

Positives

• Director Sandra Horning acquired additional common stock and stock options, indicating continued alignment of interests with shareholders.
• The acquisition of shares and options at a $0 price suggests these are likely grants as part of compensation, which is a standard practice for directors and incentivizes long-term commitment.

Future Outlook

The vesting schedule for the stock options indicates future milestones related to the director's equity compensation, contingent on her continued service to the company.

Industry Context

This filing reflects standard equity compensation practices for directors in the biotechnology or pharmaceutical industry, aiming to align director interests with long-term company performance and strategic goals.

Comparison to Industry Standards

• The grant of stock and stock options to a director is a common practice across publicly traded companies, particularly in the biotech sector, to incentivize long-term commitment and performance.
• The vesting schedule tied to continued service or an annual meeting is typical for director equity awards, similar to practices observed at comparable companies like Gilead Sciences or Amgen for their non-employee directors.
• The exercise price of $37.48 for the options would typically be compared to Revolution Medicines' stock price on the grant date to assess if they were granted at-the-money, in-the-money, or out-of-the-money, which is standard for option grants in the industry.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director aligns her interests with those of shareholders, potentially signaling confidence in the company's future performance.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The acquired stock options are subject to vesting on the earlier of June 26, 2026 (first anniversary of grant) or immediately prior to the Annual Meeting following the grant date.
• Sandra Horning must remain a Service Provider through the vesting date for the options to vest.

Key Dates

Recommendation

Keywords

Revolution Medicines, RVMD, Sandra Horning, SEC Form 4, Insider Transaction, Stock Options, Common Stock, Director Compensation, Equity Grant, Beneficial Ownership